CorMedix Amendment: Insider Tax-Withholding of 8,424 Shares Disclosed

Rhea-AI Filing Summary

CorMedix insider amendment reports a tax-withholding share disposition by Elizabeth Hurlburt, the company's Chief Operating Officer and a director. The filing shows 8,424 shares of common stock were withheld by the issuer at an effective price of $14.83 to satisfy the reporting person's tax liability, reducing her direct beneficial ownership to 176,990 shares. The Form 4/A amends an earlier filing to disclose this withheld amount. The disclosure is a mechanical equity withholding for taxes rather than an open-market sale and does not report derivative transactions.

Positive

• Amendment improves disclosure by reporting previously omitted tax-withholding shares, increasing transparency
• Transaction is a tax withholding executed by the issuer rather than a discretionary open-market sale

Negative

• Reduction in direct ownership from the tax withholding leaves the reporting person with 176,990 shares
• Initial filing omitted the withholding detail, requiring an amendment to correct records

Insights

Securities Analyst

TL;DR: Routine tax-withholding share disposition by an insider; limited investor impact.

The amendment clarifies that 8,424 shares were withheld to satisfy tax obligations at a price of $14.83, a non-market transfer executed by the issuer. This reduces the reporting person's direct ownership to 176,990 shares. For investors, this is an administrative event that typically has minimal signaling value about management's view of the company, since it is not a discretionary open-market sale.

Corporate Governance Expert

TL;DR: Disclosure correction improves transparency; nature of transaction appears routine.

The Form 4/A corrects an omission in an earlier Form 4 by reporting issuer withholding of shares for tax purposes. Timely and accurate insider reporting is important for governance and market confidence. Because the transaction is withholding to satisfy tax liability, it does not indicate a deliberate liquidity decision by the insider beyond fulfilling tax obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurlburt Elizabeth

(Last) (First) (Middle)

C/O CORMEDIX INC.

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/03/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		F		8,424	D	$14.83	176,990(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 3, 2025, the Reporting Person filed a Form 4 that omitted the Issuer's withholding of common stock to satisfy the tax liability obligation of the Reporting Person. As reported in this amendment, the Issuer withheld 8,424 shares of common stock to satisfy the tax liability obligation of the Reporting Person.

	/s/ Elizabeth Hurlburt	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Elizabeth Hurlburt report on the Form 4/A for CRMD?

The filing discloses that the issuer withheld 8,424 shares of common stock to satisfy the reporting person's tax liability, leaving 176,990 shares beneficially owned.

Was the transaction an open-market sale or issuer withholding?

The transaction was an issuer withholding of shares to cover taxes, not an open-market sale executed by the reporting person.

At what price were the withheld shares recorded?

The withheld shares are listed with a price of $14.83 per share in the Form 4/A.

What is Elizabeth Hurlburt's role at CorMedix (CRMD)?

The filing identifies Elizabeth Hurlburt as a Director and the company's Chief Operating Officer.

Does the Form 4/A report any derivative transactions by the insider?

No. Table II lists no derivative securities; the filing reports only the non-derivative withholding of common stock.